BioCentury
ARTICLE | Clinical News

ORM-12741: Phase IIa data

April 1, 2013 7:00 AM UTC

A double-blind, Finnish Phase IIa trial in 100 patients with moderate AD and behavioral symptoms showed that twice-daily flexible dosing with 30-60 mg or 100-200 mg ORM-12741 as an add-on to stable c...